Acute Kidney Injury Risk in COVID-19

NCT04874779 | Completed

• 1 other identifier: COVID-1927
• Study Type: observational
• Target: 83
• Locations: 1 country
• Sites: 1

Brief Summary

Background. Within a year, COVID-19 has advanced from being an outbreak to a pandemic, spreading rapidly and globally with devastating impact. Currently, there is an ongoing debate among scientists about the pathophysiological relationship between COVID-19 and acute kidney injury (AKI). While a few studies have concluded that the mechanisms of AKI in COVID-19 patients are seemingly multifactorial and have not been fully explicated, others asserted that AKI remains rare among COVID-19-related diseases. Considering this knowledge-gap and its potential impact on the management of COVID-19-associated AKI, our study aims to explore the prevalence of AKI and to identify possible risk factors associated with AKI development among COVID-19 hospitalized patients. Materials and Methods. This retrospective cohort study included 83 patients with COVID-19 hospitalized at AL-AHRAR Hospital, Zagazig, Egypt, between June and August,2020. Exclusion criteria were: patients younger than 18 years of age; diagnosed with end stage kidney disease; placed on maintenance dialysis; booked for a kidney transplant or on nephrotoxic medications. All patients included in the study underwent complete blood count; liver and renal function tests; examination of hemostasis parameters; inflammatory markers; serum electrolytes; routine urinalysis; arterial blood gas and non-enhanced chest and abdominal computer tomography (CT) scans

Conditions

Sever Acute Respiratory Syndrome and Acute Kidney Injury; Acute Kidney Injury

Keywords

Acute Kidney Injury

Outcome Measures

Primary Outcomes (1)

• The development of acute kidney injury or not following COVID-19

  2 months after enrollement

Study Arms (2)

Acute kidney injury (AKI) group

Acute kidney injury (AKI) group met the guidelines of Kidney Disease, Improving Global Outcomes (KDIGO)

Other: non

NON-Acute kidney injury (non-AKI) group

NON-Acute kidney injury (non-AKI) group not met the guidelines of Kidney Disease Improving Global Outcomes (KDIGO)

Other: non

Interventions

non OTHER

follow up investigations

Acute kidney injury (AKI) group; NON-Acute kidney injury (non-AKI) group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The patients' medical history, underlying diseases, medications administered at home and in hospital, laboratory data, non-enhanced chest and abdominal computer tomography (CT) scans, were retrieved from electronic medical records. According to the Ministry of Health and Population (MOHP), Egypt Management protocol for COVID-19 Patients, version 1.4, 30th May,2020, (10), all patients received standard of care treatment including: (a) oxygen supply to achieve SaO2 ≥ 90%; (b) Hydroxychloroquine (400 mg twice in first day then 200 mg twice for 6 days); (C) Vitamin C (1gm daily); (d) Zinc (50mg daily); (e) Acetylcysteine 200 mg t.d.s.; (f) lactoferrin one sachet twice daily; (g) Anticoagulation if D-dimer \> 1000.

You may qualify if:

• According to the WHO guidelines, a confirmed diagnosis of COVID-19 was defined as a positive result of a quantitative real-time reverse-transcriptase-polymerase chain reaction (RT-PCR) detection in a nasopharyngeal swab.

You may not qualify if:

• patients younger than 18 years, patients diagnosed with chronic kidney disease before admission, patients on maintenance dialysis or awaiting renal transplantation and patients taking any nephrotoxic medications a week prior to admission

Sponsors & Collaborators

• Zagazig University: lead
• University of Ha'il , Saudi Arabia.: collaborator

Study Sites (1)

Faculty of Medicine -Zagazig University

Zagazig, Egypt

Location

MeSH Terms

Conditions

Acute Kidney Injury

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Study Officials

• mohamed ghonim

  Associate professor of Internal Medicine , faculty of medicine, Zagazig University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Professor - Associate Professor of Internal Medicine- Faculty of Medicine

Study Record Dates

• First Submitted: May 2, 2021
• First Posted: May 6, 2021
• Study Start: June 8, 2020
• Primary Completion: November 18, 2020
• Study Completion: May 1, 2021
• Last Updated: July 23, 2021

Record last verified: 2021-05

Locations

EG (1)